Zhitong Finance App News, China Biopharmaceutical (01177.HK) announced that the Group's self-developed national class 1 innovative drug, Moxil capsules (trade name: Xetanxin®) have obtained marketing approval from the China National Drug Administration (NMPA) to be used in combination with fluvizil to treat patients with locally advanced hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative for previous endocrine treatment.

Zhitongcaijing · 1d ago
Zhitong Finance App News, China Biopharmaceutical (01177.HK) announced that the Group's self-developed national class 1 innovative drug, Moxil capsules (trade name: Xetanxin®) have obtained marketing approval from the China National Drug Administration (NMPA) to be used in combination with fluvizil to treat patients with locally advanced hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative for previous endocrine treatment.